Menu
Back to Journals » International Medical Case Reports Journal » Volume 3
Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
Authors Morita T
Published 19 April 2010 Volume 2010:3 Pages 39—41
DOI https://doi.org/10.2147/IMCRJ.S9441
Review by Single anonymous peer review
Peer reviewer comments 2
Tatsuo Morita
Department of Urology, Jichi Medical University, Tochigi, Japan
Abstract: A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estramustine phosphate (EMP) because of the progression to hormone-refractory prostate cancer (HRPC). Leukocytosis over 20000/μL was repeatedly observed at each administration of EMP. This is the first case report of leukocytosis in response to EMP in an HRPC patient. The present case suggests that EMP could modulate leukocyte differentiation in HRPC patients.
Keywords: leukocytosis, neutrophilia, estramustine phosphate, hormone-refractory prostate cancer
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.